{"Clinical Trial ID": "NCT00121992", "Intervention": ["INTERVENTION 1:", "- Arm A: AEC", "5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv day 1, every 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv", "5-fluorouracil", "Doxorubicin", "- Cyclophosphamide", "INTERVENTION 2:", "Army B: TAC", "TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv day 1, every 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv", "Docetaxel", "Doxorubicin", "- Cyclophosphamide"], "Eligibility": ["Incorporation criteria:", "Written consent with knowledge of the case", "\u2022 Patients with breast cancer (T1-T3) with negative axillary lymph nodes (10 dissection of axillary lymph nodes) and high risk criteria according to St. Gallen consensus criteria.", "The interval between surgery and registration is less than 60 days.", "The final surgical treatment must be either mastectomy or conservative breast surgery. The margins of the resected sample of surgery must be free of invasive adenocarcinoma and in-situ canalal carcinoma. In-situ lobular carcinoma is not considered a positive margin.", "Patients without proven metastatic disease.", "The estrogen and progesterone receptors were performed on the primary tumour prior to randomization.", "The age between 18 and 70 years.", "Karnofsky Performance Index > 80%.", "Adequate liver, kidney and heart function.", "Adequate hematology level.", "Negative pregnancy test", "- Exclusion criteria:", "A prior systemic anticancer treatment for breast cancer (immunotherapy, hormone therapy, chemotherapy).", "An anterior anthracycline or taxoids (pallitaxel, docetaxel) for any malignancy.", "- Prior radiation therapy for breast cancer.", "Invasive bilateral breast cancer.", "* Patients in pregnancy or lactation.", "Patients of childbearing potential should implement adequate non-hormonal contraceptive measures during study treatment.", "Any T4 or N1-3 or M1 breast cancer.", "Based on NCI criteria, pre-existing motor or sensory neurotoxicity of grade 2 severity.", "Other serious illness or health status", "Previous or present history of neoplasm other than breast carcinoma.", "The ipsilateral in-situ channel carcinoma (CDIS) of the breast.", "The in-situ lobular carcinoma (ILC) of the breast.", "Chronic corticosteroid therapy unless initiated > 6 months prior to entry into the study and at low dose", "\u2022 Concomitant treatment with ovarian hormone replacement therapy. Prior treatment should be discontinued prior to entry into the study.", "Description of contraindications for the use of corticosteroids.", "- Concomitant treatment with other experimental medicinal products.", "Participation in another clinical trial with any non-marketed experimental drug within 30 days of entry into the study.", "- Concomitant treatment with any other anticancer treatment.", "* Male patients."], "Results": ["Performance measures:", "\u2022 Disease-free survival events (DFS)", "The DFS is calculated from the date of randomization to the first date of local, regional or distant recurrence, second primary or death tumour.", "Time limit: 10 years", "Results 1:", "Title of the arm/group: Arm A: AEC", "Description of the arm/group: AEC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv day 1, every 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv", "5-fluorouracil", "Doxorubicin", "- Cyclophosphamide", "Total number of participants analysed: 521", "Type of measurement: Number", "Unit of measure: events 127", "Results 2:", "Title of arm/group: Arm B: TAC", "Description of the arm/group: TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv day 1, every 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv", "Docetaxel", "Doxorubicin", "- Cyclophosphamide", "Total number of participants analysed: 539", "Type of measurement: Number", "Unit of measure: events 112"], "Adverse Events": ["Undesirable Events 1:", "Total: 21/519 (4.05%)", "Anemia 1/519 (0.19%)", "Bilirubin 0/519 (0.00 %)", "- Leucopenia 0/519 (0.00 %)", "Neutropenia 1/519 (0.19%)", "Arrhythmia 0/519 (0.00 %)", "Carotid artery thrombosis 1/519 (0.19%)", "- Ear infection 0/519 (0.00 %)", "Conjunctivitis 0/519 (0.00 %)", "Abdominal pain 1/519 (0.19%)", "- Anal fissure 0/519 (0.00 %)", "Constipation 0/519 (0.00 %)", "Diarrhoea 1/519 (0.19%)", "Adverse Events 2:", "Total: 119/532 (22.37%)", "Anemia 1/532 (0.19%)", "Bilirubin 1/532 (0.19%)", "- Leucopenia 1/532 (0.19%)", "Neutropenia 5/532 (0.94%)", "Arrhythmia 1/532 (0.19%)", "Carotid artery thrombosis 0/532 (0.00 %)", "Ear infection 1/532 (0.19%)", "Conjunctivitis 1/532 (0.19%)", "Abdominal pain 1/532 (0.19%)", "Anal fissure 1/532 (0.19%)", "Constipation 1/532 (0.19%)", "Diarrhoea 6/532 (1.13%)"]}